Christoph Varenhorst

Summary

Affiliation: Uppsala University Hospital
Country: Sweden

Publications

  1. ncbi Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery
    Christoph Varenhorst
    Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden Electronic address
    J Am Coll Cardiol 60:1623-30. 2012
  2. ncbi Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin
    Christoph Varenhorst
    Uppsala Clinical Research Center, Department Medical Sciences and Cardiology, Uppsala University, Sweden
    Am Heart J 157:562.e1-9. 2009
  3. ncbi Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
    Christoph Varenhorst
    Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
    Eur Heart J 30:1744-52. 2009
  4. ncbi Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study
    Christoph Varenhorst
    Uppsala Clinical Research Center, Department of Medical Sciences, Cardiology, Uppsala University, Sweden
    Am Heart J 162:363-71. 2011
  5. ncbi Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease
    Oscar O Braun
    Department of Medical Sciences, Clinical Chemistry, Akademiska Hospital, Uppsala, Sweden
    Thromb Haemost 100:626-33. 2008
  6. ncbi Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
    Lars Wallentin
    Department of Medical Sciences and Cardiology, Uppsala Clinical Research Center, University Hospital, 751 85 Uppsala, Sweden
    Eur Heart J 29:21-30. 2008
  7. ncbi Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    Lars Wallentin
    Uppsala Clinical Research Center, Uppsala, Sweden
    N Engl J Med 361:1045-57. 2009
  8. ncbi Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)?
    Christoph Varenhorst
    Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
    Curr Cardiol Rep 14:486-92. 2012

Detail Information

Publications8

  1. ncbi Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery
    Christoph Varenhorst
    Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden Electronic address
    J Am Coll Cardiol 60:1623-30. 2012
    ..This study investigated the differences in specific causes of post-coronary artery bypass graft surgery (CABG) deaths in the PLATO (Platelet Inhibition and Patient Outcomes) trial...
  2. ncbi Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin
    Christoph Varenhorst
    Uppsala Clinical Research Center, Department Medical Sciences and Cardiology, Uppsala University, Sweden
    Am Heart J 157:562.e1-9. 2009
    ..These tests need to be evaluated in comparison to reference measurements of P2Y(12) function during different thienopyridine treatments...
  3. ncbi Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
    Christoph Varenhorst
    Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
    Eur Heart J 30:1744-52. 2009
    ..We hypothesized that decreased CYP2C19 activity affects the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel...
  4. ncbi Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study
    Christoph Varenhorst
    Uppsala Clinical Research Center, Department of Medical Sciences, Cardiology, Uppsala University, Sweden
    Am Heart J 162:363-71. 2011
    ..On-clopidogrel platelet reactivity was investigated in patients with previous angiographically confirmed STh, myocardial infarction (MI), and controls...
  5. ncbi Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease
    Oscar O Braun
    Department of Medical Sciences, Clinical Chemistry, Akademiska Hospital, Uppsala, Sweden
    Thromb Haemost 100:626-33. 2008
    ..Attenuated platelet aggregation and reduced expression of platelet pro-coagulant and pro-inflammatory markers with prasugrel suggest the potential to reduce cardiovascular events both in the acute setting and in long-term treatment...
  6. ncbi Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
    Lars Wallentin
    Department of Medical Sciences and Cardiology, Uppsala Clinical Research Center, University Hospital, 751 85 Uppsala, Sweden
    Eur Heart J 29:21-30. 2008
    ..P2Y(12) receptor antagonism and platelet inhibition by prasugrel vs. clopidogrel were investigated in patients with stable coronary artery disease...
  7. ncbi Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    Lars Wallentin
    Uppsala Clinical Research Center, Uppsala, Sweden
    N Engl J Med 361:1045-57. 2009
    ..Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel...
  8. ncbi Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)?
    Christoph Varenhorst
    Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
    Curr Cardiol Rep 14:486-92. 2012
    ..This review provides recommendations for their optimal use...